Vaklavas, Christos http://orcid.org/0000-0002-9919-2748
Stringer-Reasor, Erica M. http://orcid.org/0000-0002-1862-3367
Elkhanany, Ahmed M. http://orcid.org/0000-0001-7681-6872
Ryan, Kevin J.
Li, Yufeng
Theuer, Charles P. http://orcid.org/0000-0003-2826-4051
Acosta, Edward P.
Wei, Shi
Yang, Eddy S. http://orcid.org/0000-0002-6450-2638
Grizzle, William E. http://orcid.org/0000-0001-9245-0401
Forero-Torres, Andres http://orcid.org/0000-0001-5161-8319
Funding for this research was provided by:
UAB Young Supporters Board
Article History
Received: 17 October 2022
Accepted: 16 January 2023
First Online: 3 February 2023
Declarations
:
: C.V. consulting or advisory board: Guidepoint, Novartis, SeaGen, Daiichi Sankyo, Genentech (unpaid); research funding (paid to the institution): Pfizer, SeaGen, H3 Biomedicine/Eisai, AstraZeneca, CytomX; employment: Flatiron (wife); Other: Gilead, AstraZeneca. Open payments link: ExternalRef removed; A.F.T. received support from Genentech to conduct clinical and laboratory research (paid to the University of Alabama at Birmingham). A.F.T. is currently an employee of SeaGen. The remaining authors have no conflict of interest to disclose.
: The protocol was reviewed and approved by the Institutional Review Board of the University of Alabama at Birmingham, and the study followed the Declaration of Helsinki and Good Clinical Practice guidelines. All patients gave informed consent. This study is registered on the clinical trial website of the US National Cancer Institute (ExternalRef removed).